Colorectal Adenocarcinoma

P1, N=300, Recruiting, M.D. Anderson Cancer Center | Active, not recruiting --> Recruiting | N=117 --> 300

RMSD and RMSF analyses revealed that naringin, the major compound of I. aschersoniana, exhibited dynamically stable binding within the active sites of AKT1, EGFR, and PPARG proteins, with AKT1@Naringin and PPARG@Naringin complexes displaying a more stable dynamic profile. In this network pharmacology study, forty-five common targets between the major compounds of I. aschersoniana with breast and colon cancers were identified.

This study suggests that CCL3 could serve as a potential prognostic marker for COAD and other cancers. Because CCL3 expression was strongly associated with immune modulation within the tumor microenvironment, this pointed out that CCL3 could serve as a promising therapeutic target with significant implications for immunotherapy and chemotherapy response.

These findings suggest that increased RUVBL1 expression is associated with poor prognosis and altered immune infiltration in COAD patients. RUVBL1 may serve as a potential therapeutic target for COAD.

A perioperative, biomarker-guided integrative program targeting inflammatory and immunometabolic vulnerability was associated with improved psychosocial and functional recovery after APR, with favorable effects on immune restoration and exploratory survival outcomes, and with excellent safety and adherence. Longer follow-up will be required to determine whether the observed immune and survival benefits remain durable over time.

In older adults with rectal cancer, robotic surgery was associated with significant reduction in conversion rates and potentially modestly improved lymph node harvest, while both approaches provided comparable safety and long-term oncologic outcomes.These findings must be considered in the context of the heterogenous definitions of conversion and the availability of the robotic platform and training in both robotic and laparoscopic technqiues.

P2, N=88, Recruiting, University College, London | Trial completion date: Dec 2028 --> Jul 2029 | Trial primary completion date: Feb 2026 --> Jul 2026

P1, N=130, Not yet recruiting, Bayer

A minimally invasive subtotal colectomy was proposed to a 41-year-old man whose genetic testing for polyposis and hereditary cancer syndromes revealed a rare homozygotic variation of uncertain significance (VUS)+ in the MUTYH gene. Absence of rectal involvement made rectal sparing possible in association with close endoscopic follow-up.

Together, these articles reposition KRASG12R PDAC as a biologically constrained yet therapeutically exploitable subtype. See related article by Burge et al., p. 1854 See related article by Burge et al., p. 1868 See related article by Kamgar et al., p. 2042.

P2, N=50, Active, not recruiting, Providence Health & Services | Trial completion date: Dec 2025 --> Dec 2026

Our findings debate the WHO 50% mucin threshold, showing that tumors with 5-50% mucin exhibit comparable aggressiveness to classical MAC. Integrating molecular profiling with histology may improve risk stratification and guide tailored therapeutic strategies for mucinous CRC, regardless of mucin proportion.